Brief: Geneuro: Publication Confirms Preclinical Therapeutic Effect Of Anti-HERV-K ENV Antibody
20/07/2022 06:34
July 20 (Reuters) - Geneuro SA GNRO.PA :
* ONLINE PUBLICATION OF HERV-K ENV'S MECHANISM OF ACTION IN
SPORADIC AMYOTROPHIC LATERAL SCLEROSIS (ALS) LEADING TO MOTOR
NEURON DEATH
* PUBLICATION CONFIRMS PRECLINICAL THERAPEUTIC EFFECT OF
GENEURO'
S ANTI-HERV-K ENV ANTIBODY IN NEUTRALIZING HERV-K ENV TOXICITY
Source text for Eikon: ID:nBw8TfcXra
Further company coverage: GNRO.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Geneuro SA
See all newsBrief: Geneuro SA Postpones Publication Of Half-Yearly Financial Report
Brief: Geneuro SA Announces Extension Of Its Definitive Debt-Restructuring Moratorium
Brief: Geneuro SA Announces The Opening Of Receivership Proceedings For Its French Subsidiary Geneuro Innovation Sas
Brief: Geneuro Confirms Top-Line Results In Its Post-Covid Trial By End-June
Brief: Geneuro announces EUR 5 Mln private placement